The prevalence of obesity and diabetes continues to rise in the United States and worldwide. These findings parallel the expansion of childhood obesity and diabetes. Obesity is a central component of the cardiorenal metabolic syndrome (CRS) which increases the risk for cardiovascular disease (CVD) and chronic kidney disease (CKD). The hallmark of obesity, CRS, and early type 2 diabetes is insulin resistance, a result of decreased insulin metabolic signaling due, in part, to enhanced serine phosphorylation and/or proteasome-mediated degradation of the insulin receptor substrate. Cardiovascular and renal insulin resistance significantly contributes to endothelial dysfunction, impaired cardiac diastolic and vascular relaxation, glomerular injury, and tubular dysfunction. In this context, multiple factors including oxidative stress, increased inflammation, and inappropriate activation of the renin-angiotensin-aldosterone and the sympathetic nervous system contribute to overweight- and obesity-induced systemic and tissue insulin resistance. One common link between obesity and the development of insulin resistance appears to be a low-grade inflammatory response resulting from dysfunctional innate and adaptive immunity. In this regard, there has been recent work on the role of dipeptidyl peptidase-4 (DPP-4) in modulating innate and adaptive immunity. The direct effects of DPP-4 on immune cells and the indirect effects through GLP-1-dependent and -independent pathways suggest effects of DPP-4 inhibition may have beneficial effects beyond glycemic control in improving CVD and renal outcomes. Accordingly, this review addresses new insights into the role of DPP-4 in immune modulation and the potential beneficial effects of DPP-4 inhibitors in insulin resistance and associated CVD and CKD prevention.

Keywords:
DPP-4, Cardiorenal syndrome, Obesity, Diabetes, Insulin resistance
1.
Reaven GM: Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am 2011;95:875-892.
2.
Sowers JR: Obesity as a cardiovascular risk factor. Am J Med 2003;115(suppl 8A):37S-41S.
3.
Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM: Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-1555.
4.
McGee DL; Diverse Populations Collaboration: Body mass index and mortality: a meta-analysis based on person-level data from twenty-six observational studies. Ann Epidemiol 2005;15:87-97.
5.
Ghandehari H, Le V, Kamal-Bahl S, Bassin SL, Wong ND: Abdominal obesity and the spectrum of global cardiometabolic risks in US adults. Int J Obes (Lond) 2009;33:239-248.
6.
Sowers JR, Whaley-Connell A, Hayden MR: The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med 2011;1:5-12.
7.
McCullough AJ: Epidemiology of the metabolic syndrome in the USA. J Dig Dis 2011;12:333-340.
8.
Flegal KM, Carroll MD, Ogden CL, Curtin LR: Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-241.
9.
Ogden CL, Carroll MD, Flegal KM: High body mass index for age among US children and adolescents, 2003-2006. JAMA 2008;299:2401-2405.
10.
Allcock DM, Gardner MJ, Sowers JR: Relation between childhood obesity and adult cardiovascular risk. Int J Pediatr Endocrinol 2009;2009:108187.
11.
Bakris G, Vassalotti J, Ritz E, Wanner C, Stergiou G, Molitch M, Nesto R, Kaysen GA, Sowers JR; CKD Consensus Working Group: National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int 2010;78:726-736.
12.
Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ: A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006;290:F625-F631.
13.
Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI, Kang DH, Gersch MS, Benner S, Sánchez-Lozada LG: Potential role of sugar (fructose) in the epidemic of hypertension, obesity, and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 2007;86:899-906.
14.
Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG: Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 2002;51:3020-3024.
15.
Wong C, Marwick TH: Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med 2007;4:436-443.
16.
Witteles RM, Fowler MB: Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008;51:93-102.
17.
Sowers JR: Metabolic risk factors and renal disease. Kidney Int 2007;71:719-720.
18.
Kurella M, Lo JC, Chertow GM: Metabolic syndrome and the risk of chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16:2134-2140.
19.
Whaley-Connell A, Pavey BS, McCullough PA, Saab G, Li S, McFarlane SI, Chen SC, Vassalotti JA, Collins AJ, Bakris G, Sowers JR; KEEP Investigators: Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich) 2010;12:51-58.
20.
Tanner RM, Brown TM, Muntner P: Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease. Curr Hypertens Rep 2012;14:152-159.
21.
Thethi T, Kamiyama M, Kobori H: The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep 2012;14:160-169.
22.
Johns BR, Pao AC, Kim SH: Metabolic syndrome, insulin resistance and kidney function in non-diabetic individuals. Nephrol Dial Transplant 2012;27:1410-1415.
23.
Maric C, Hall JE: Obesity, metabolic syndrome and diabetic nephropathy. Contrib Nephrol 2011;170:28-35.
24.
Gray S, Kim JK: New insights into insulin resistance in the diabetic heart. Trends Endocrinol Metab 2011;22:394-403.
25.
Bertrand L, Horman S, Beauloye C, Vanoverschelde JL: Insulin signaling in the heart. Cardiovasc Res 2008;79:238-248.
26.
Muniyappa R, Montagnani M, Koh KK, Quon MJ: Cardiovascular actions of insulin. Endocr Rev 2007;28:463-491.
27.
Mandavia CH, Aroor AR, Demarco VG, Sowers JR: Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci 2012 DOI: 10.1016/j.lfs.2012.10.028.
28.
Kim JA, Jang HJ, Martinez-Lemus LA, Sowers JR: Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab 2012;302:E201-E208.
29.
Zhang J, Gao Z, Yin J, Quon MJ, Ye J: S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2. J Biol Chem 2008;283:35375-35382.
30.
Isenović E, Muniyappa R, Milivojević N, Rao Y, Sowers JR: Role of PI3-kinase in isoproterenol and IGF-1 induced eNOS activity. Biochem Biophys Res Commun 2001;285:954-958.
31.
Kim YB, Kalinowski A, Russell KS, Kim JK: Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes 2005;54:3530-3540.
32.
Demarco VG, Ford DA, Henriksen EJ, Aroor AR, Johnson MS, Habibi J, Ma L, Yang M, Albert CJ, Lally JW, Ford CA, Prasannarong M, Hayden MR, Whaley-Connell AT, Sowers JR: Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice. Endocrinology 2013;154:159-171.
33.
Aroor AR, Mandavia C, Ren J, Sowers JR, Pulakat L: Mitochondria and oxidative stress in the cardiorenal metabolic syndrome. Cardiorenal Med 2012;2:87-109.
34.
Kalupahana NS, Moustaid-Moussa N, Claycombe KJ: Immunity as a link between obesity and insulin resistance. Mol Aspects Med 2012;33:26-34.
35.
Romeo GR, Lee J, Shoelson SE: Metabolic syndrome, insulin resistance, and roles of inflammation - mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol 2012;32:1771-1776.
36.
Scarpellini E, Tack J: Obesity and metabolic syndrome: an inflammatory condition. Dig Dis 2012;30:148-153.
37.
Olefsky JM, Glass CK: Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219-246.
38.
Sun S, Ji Y, Kersten S, Qi L: Mechanisms of inflammatory responses in obese adipose tissue. Annu Rev Nutr 2012;32:261-286.
39.
Sell H, Eckel J: Adipose tissue inflammation: novel insight into the role of macrophages and lymphocytes. Curr Opin Clin Nutr Metab Care 2010,13:366-370.
40.
Rocha VZ, Folco EJ: Inflammatory concepts of obesity. Int J Inflam 2011;2011:529061.
41.
Kamizato M, Nishida K, Masuda K, Takeo K, Yamamoto Y, Kawai T, Teshima-Kondo S, Tanahashi T, Rokutan K: Interleukin 10 inhibits interferon gamma- and tumor necrosis factor alpha-stimulated activation of NADPH oxidase 1 in human colonic epithelial cells and the mouse colon. J Gastroenterol 2009;44:1172-1184.
42.
Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldfine AB, Benoist C, Shoelson S, Mathis D: Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009;15:930-939.
43.
Kassan M, Galan M, Partyka M, Trebak M, Matrougui K: Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler Thromb Vasc Biol 2011;31:2534-2542.
44.
Procaccini C, Carbone F, Galgani M, La Rocca C, De Rosa V, Cassano S, Matarese G: Obesity and susceptibility to autoimmune diseases. Expert Rev Clin Immunol 2011;7:287-294.
45.
Ilan Y, Maron R, Tukpah AM, Maioli TU, Murugaiyan G, Yang K, Wu HY, Weiner HL: Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci USA 2010;107:9765-9770.
46.
Hamaguchi M, Sakaguchi S: Regulatory T cells expressing PPAR-γ control inflammation in obesity. Cell Metab 2012;16:4-6.
47.
Li K, Xu W, Guo Q, Jiang Z, Wang P, Yue Y, Xiong S: Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ Res 2009;105:353-364.
48.
Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, Rahn HP, Plehm R, Wellner M, Elitok S, Gratze P, Dechend R, Luft FC, Muller DN: Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 2009;119:2904-2912.
49.
Liu XH, Ji QW, Huang Y, Zeng QT: Th17 response promotes angiotensin II-induced atherosclerosis. Med Hypotheses 2011;76:593-595.
50.
Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG: Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010;55:500-507.
51.
Mikhail N: Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease. Postgrad Med 2012;124:138-144.
52.
Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y: Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 2012;60:833-841.
53.
Fadini GP, Avogaro A: Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011;55:10-16.
54.
Lenski M, Kazakov A, Marx N, Böhm M, Laufs U: Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol 2011;51:906-918.
55.
Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, Cheng XW, Okumura T, Hirashiki A, Nagata K, Murohara T: Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 2012;126:1838-1851.
56.
Hocher B, Reichetzeder C, Alter ML: Renal and cardiac effects of DPP-4 inhibitors - from preclinical development to clinical research. Kidney Blood Press Res 2012;36:65-84.
57.
Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T: The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol 2012, E-pub ahead of print.
58.
Kröller-Schön S, Knorr M, Hausding M, Oelze M, Schuff A, Schell R, Sudowe S, Scholz A, Daub S, Karbach S, Kossmann S, Gori T, Wenzel P, Schulz E, Grabbe S, Klein T, Münzel T, Daiber A: Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 2012;96:140-149.
59.
Queiroz-Leite GD, Peruzzetto MC, Neri EA, Rebouças NA: Transcriptional regulation of the Na⁺/H⁺ exchanger NHE3 by chronic exposure to angiotensin II in renal epithelial cells. Biochem Biophys Res Commun 2011;409:470-476.
60.
Banday AA, Siddiqui AH, Menezes MM, Hussain T: Insulin treatment enhances AT1 receptor function in OK cells. Am J Physiol Renal Physiol 2005;288:F1213-F1219.
61.
Girardi AC, Fukuda LE, Rossoni LV, Malnic G, Rebouças NA: Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol 2008;294:F414-F422.
62.
Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS: Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012;340:248-255.
63.
Yang J, Campitelli J, Hu G, Lin Y, Luo J, Xue C: Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci 2007;81:272-279.
64.
Yazbeck R, Howarth GS, Abbott CA: Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600-607.
65.
Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, Amo K, Aoki K, Morimoto C, Takeda E, Terauchi Y: Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011;60:1246-1257.
66.
Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, Odori S, Kono S, Hasegawa K, Shimatsu A: A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism 2013;62:347-351.
67.
Schürmann C, Linke A, Engelmann-Pilger K, Steinmetz C, Mark M, Pfeilschifter J, Klein T, Frank S: The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. Pharmacol Exp Ther 2012;342:71-80.
68.
Koren S, Shemesh-Bar L, Tirosh A, Peleg RK, Berman S, Hamad RA, Vinker S, Golik A, Efrati S: The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther 2012;14:561-567.
69.
Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, Sun Q, Mihai G, Maiseyeu A, Rajagopalan S: Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011;124:2338-2349.
70.
Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y: DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011;58:157-166.
71.
Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ: Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 2010;53:730-740.
72.
Rodriguez R, Viscarra JA, Minas JN, Nakano D, Nishiyama A, Ortiz RM: Angiotensin receptor blockade increases pancreatic insulin secretion and decreases glucose intolerance during glucose supplementation in a model of metabolic syndrome. Endocrinology 2012;153:1684-1695.
73.
Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, Schiffrin EL: T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 2012;59:324-330.
74.
Liang J, Leung KK, Lam SY, Leung PS: Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells. Diabetes Obes Metab 2012;14:842-851.
75.
Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, Raila J, Henze A, Klein T, Hocher B: DPP-4 Inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012;36:119-130.
76.
Shevach EM: Application of IL-2 therapy to target T regulatory cell function. Trends Immunol 2012;33:626-632.
77.
Zou T, Satake A, Corbo-Rodgers E, Schmidt AM, Farrar MA, Maltzman JS, Kambayashi T: Cutting edge: IL-2 signals determine the degree of TCR signaling necessary to support regulatory T cell proliferation in vivo. J Immunol 2012;189:28-32.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.